Co-Diagnostics (NASDAQ:CODX) Given Neutral Rating at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Co-Diagnostics (NASDAQ:CODX) in a research note released on Monday morning,Benzinga reports. HC Wainwright currently has a $1.50 target price on the stock.

Co-Diagnostics Stock Up 3.5 %

CODX opened at $1.18 on Monday. Co-Diagnostics has a twelve month low of $1.00 and a twelve month high of $2.23. The company has a fifty day moving average of $1.25 and a 200-day moving average of $1.26. The stock has a market cap of $37.65 million, a PE ratio of -0.86 and a beta of -0.84.

Institutional Investors Weigh In On Co-Diagnostics

A hedge fund recently bought a new stake in Co-Diagnostics stock. Koss Olinger Consulting LLC purchased a new position in Co-Diagnostics, Inc. (NASDAQ:CODX) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 58,887 shares of the company’s stock, valued at approximately $74,000. Koss Olinger Consulting LLC owned 0.19% of Co-Diagnostics at the end of the most recent quarter. 14.99% of the stock is owned by institutional investors and hedge funds.

About Co-Diagnostics

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.